The challenge of finding a cure for HIV infection

DD Richman, DM Margolis, M Delaney, WC Greene… - Science, 2009 - science.org
Although combination therapy for HIV infection represents a triumph for modern medicine,
chronic suppressive therapy is required to contain persistent infection in reservoirs such as …

Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis

SA Bustin, R Mueller - Clinical Science, 2005 - portlandpress.com
qRT-PCR (real-time reverse transcription-PCR) has become the benchmark for the detection
and quantification of RNA targets and is being utilized increasingly in novel clinical …

[HTML][HTML] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

I Levy, A Wieder-Finesod, V Litchevsky, A Biber… - Clinical Microbiology …, 2021 - Elsevier
Objectives The immunogenicity and safety of the Pfizer-BioNTech BNT162b2 mRNA vaccine
in people living with human immunodeficiency virus type 1 (PLWH) are unknown. We aimed …

T Cell Activation Is Associated with Lower CD4+ T Cell Gains in Human Immunodeficiency Virus-Infected Patients with Sustained Viral Suppression during …

PW Hunt, JN Martin, E Sinclair, B Bredt… - The Journal of …, 2003 - academic.oup.com
Although T cell activation is associated with disease progression in untreated human
immunodeficiency virus type 1 (HIV-1) infection, its significance in antiretroviral-treated …

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

S Palmer, F Maldarelli, A Wiegand… - Proceedings of the …, 2008 - National Acad Sciences
Residual viremia can be detected in most HIV-1-infected patients on antiretroviral therapy
despite suppression of plasma RNA to< 50 copies per ml, but the source and duration of this …

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

S Palmer, AP Wiegand, F Maldarelli… - Journal of clinical …, 2003 - Am Soc Microbiol
More sensitive assays for human immunodeficiency virus type 1 (HIV-1) RNA are needed to
detect, quantify, and characterize persistent viremia in patients who are receiving …

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

MS Sulkowski, JJ Eron, D Wyles, R Trinh, J Lalezari… - Jama, 2015 - jamanetwork.com
Importance Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C
virus (HCV) are at high risk for liver disease progression. However, interferon-based …

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel

PG Yeni, SM Hammer, CCJ Carpenter, DA Cooper… - Jama, 2002 - jamanetwork.com
ObjectiveNew information warrants updated recommendations for the 4 central issues in
antiretroviral therapy: when to start, what drugs to start with, when to change, and what to …

Viral and host mediators of non-suppressible HIV-1 viremia

A Mohammadi, B Etemad, X Zhang, Y Li, GJ Bedwell… - Nature Medicine, 2023 - nature.com
Abstract Non-suppressible HIV-1 viremia (NSV) is defined as persistent low-level viremia on
antiretroviral therapy (ART) without evidence of ART non-adherence or significant drug …

British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in …

Writing Group, I Williams, D Churchill… - HIV …, 2014 - Wiley Online Library
1.4 Resource use 1.5 Implications for research 1.6 References 2.0 Recommendations and
auditable outcomes 2.1 Recommendations (GRADE) 2.1. 1 Patient involvement in decision …